- Home
- AQB vs GLMD Comparison
AQB vs GLMD Comparison
Compare AQB & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AQB | GLMD |
|---|---|---|
| Founded | 1991 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.0M |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AQB | GLMD |
|---|---|---|
| Price | $1.03 | $0.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.2K | ★ 71.6K |
| Earning Date | 05-14-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.66 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,472,659.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $0.41 |
| 52 Week High | $2.95 | $2.34 |
Technical Indicators
Market Signals| Indicator | AQB | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 67.23 |
| Support Level | $1.01 | $0.74 |
| Resistance Level | $1.06 | $0.87 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 73.80 | 88.91 |
Price Performance
Historical ComparisonAbout AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.